These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27385296)

  • 1. Re-admissions for delayed complications after cytoreductive surgery and HIPEC.
    Spiliotis J; Argiriou EO; Vafias E; Manou V; Vaos N; Datsis A; Efstathiou E
    Acta Chir Belg; 2016 Apr; 116(2):96-100. PubMed ID: 27385296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
    Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
    Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands.
    van Oudheusden TR; Lemmens VE; Braam HJ; van Ramshorst B; Meijerink J; te Velde EA; Mehta AM; Verwaal VJ; de Hingh IH
    Surgery; 2015 Jun; 157(6):1023-7. PubMed ID: 25818658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
    van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies.
    Dreznik Y; Hoffman A; Hamburger T; Ben-Yaacov A; Dux Y; Jacoby H; Berger Y; Nissan A; Gutman M
    Surgeon; 2018 Oct; 16(5):278-282. PubMed ID: 29429947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive care unit hospitalization after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Spiliotis J; Argiriou EO; Kopanakis N; Vaos N; Rogdakis A; Kastrinaki K; Vaxevanidou A; Zakka M; Kalaidopoulou U; Efstathiou E
    J BUON; 2016; 21(3):726-31. PubMed ID: 27569096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
    Naffouje SA; O'Donoghue C; Salti GI
    J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
    Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis.
    Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH
    Ann Surg Oncol; 2016 Mar; 23(3):833-41. PubMed ID: 26442921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score.
    Malfroy S; Wallet F; Maucort-Boulch D; Chardonnal L; Sens N; Friggeri A; Passot G; Glehen O; Piriou V
    Surg Oncol; 2016 Mar; 25(1):6-15. PubMed ID: 26979635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Rottenstreich A; Kalish Y; Kleinstern G; Yaacov AB; Dux J; Nissan A
    J Surg Oncol; 2017 Dec; 116(7):914-920. PubMed ID: 28650573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a concomitant urologic procedure on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Lyon TD; Turner Ii RM; Nikonow TN; Wang L; Uy J; Ramalingam L; Holtzman MP; Pingpank JF; Bartlett DL; Davies BJ
    J Surg Oncol; 2016 Feb; 113(2):218-22. PubMed ID: 26775909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.